

**Fanvestments Corporation**  
*Global Investments - Global Returns*  
Invest today, Build Wealth Forever

FVAM Fund Quarterly Portfolio Report  
Q4 - 2018

***Fanvestments FVAM Diversified Multi-Asset Private Alternative Investment Fund (FVAM)***

This Report describes the Fanvestments Diversified Multi-Asset Private Alternative Investment Fund (the "Fund", "FVAM"). Fanvestments Corporation (the "Management"), a Rhode Island S-Corporation, serves as the Fund's Management Business. The following summary highlights information about the fund, during and as of the 4th Quarter of 2018 (October thru December), and info about the fund's investment strategy and expectations. Except where the context otherwise requires or indicates, in this report, (i) "Fanvestments," "the Business," "we," "us", "Firm", "management" and "our" refer to Fanvestments Corporation and/or owner, and its Primary offering, with respect to FVAM, a Private Alternative Investment Fund, referred to as "the Fund", "the portfolio", or "FVAM".

Contact and Social Media:  
Fanvestments, Corporation  
Matthew Fanning – Owner / Founder / CIO / Fund Manager  
[mfanning@fanvestments.com](mailto:mfanning@fanvestments.com)  
[www.fanvestments.com](http://www.fanvestments.com)  
Twitter: @fanvestments  
[facebook.com/fanvestments](https://facebook.com/fanvestments)  
Instagram: fanvestments

## **PRINCIPAL INVESTMENT STRATEGY**

The FVAM Fund consists of a diversified portfolio of mixed asset-types, with a majority focus on equity investments ("stocks"), as well as fixed income (bonds and credit), commodities and currencies, for the goal of price & capital appreciation, and to drive long-term positive durable returns through all types of economic and global financial cycles. FVAM's primary exposure focus is mostly within individual stocks with a long-bias, and some stock ETF exposure. Fund applies multiple strategies, from fundamental research such as earnings, revenue, growth rates, and valuation, analysing historical data and future expectations. Combining that with technical analysis, studying charts for trends, as well as trend change, price and timeframe analysis, overbought and oversold indicators, volume spikes leading to capitulation. For investment style, looking for growth and value, "Growth at a Great Value". The macro environment is very important as well, and will overlay the macro environment on top of the other research and overall portfolio analysis. Other strategies, more of a focus within a sector, such as biotech, looking for companies that are trying to find the cure for major diseases. Within Technology, to find innovation driving the future, such as AI, Big Data, Cloud, Analytics, FinTech (such as mobile payments), as well as to find the Founders that are all-in and have a sense of brilliance. Price and Returns tends to trump timeframe, but the fund does expect to hold most investments for multiple years, mid-to-long term. The Fund is actively-managed with a blended investment style, looking for Growth at a great Value, more of a "buy the blood" , buy low-sell high, as a fundamental mindset. Fund will also seek to find opportunity within event-driven strategies, such as mergers, FDA approvals, momentum and fund flows, as well as unusual options action and potential buy-out/merger opportunities. Part of the investment style is to bring together a diversified multi-asset "401k retirement" portfolio approach, combined with hedge fund, institutional style investing involving individual stock picking along side minimal hedging against general market risk, as well as having low market correlation producing fund-specific returns. "401k meets Alternative Investment fund". The FVAM fund will also invest in other investment funds and ETFs from time to time, for opportunity and to obtain that much more diversification, and to lower overall volatility and risk. Searching all size business all around the world, but currently limited to only investing within U.S. exchanges. Only on a limited basis, and kept to very small exposure at most times, the fund does use multiple hedging strategies to protect from general stock market volatility, as well as downside risk within individual positions, or macro issues such as economic cycles, recessions, geopolitics. In most hedge cases, fund will utilize options strategies for short exposure vs outright selling short, such as index/ETF options, VIX (volatility) options, positional hedges (puts or covered calls). Overall hedging exposure is kept low, utilizing more of a hedge by allocation strategy, i.e... Position sizing, always monitoring positional exposure relative to risk of that position and overall portfolio size. As well as other portfolio management strategies - performance monitoring and risk management. Such as selling portions of gains, decreasing higher risk, increase lower risk (lower reward) exposure, such as bonds, money market and cash. Since FVAM is not intending to mirror, or match the assets or performance of any other index or ETF, the fund's performance will not have intention to directly match the performance of any other investment vehicle, ETF, or Index or have the same timing as the overall markets. An index, like the S&P 500, is also a collection of assets, with ~500 individual stock holdings. FVAM's intent is to have created its own unique investment vehicle, a diversified multi-asset fund (stocks, bonds, ETFs), with individual assets selected by Fanvestments Management, minimal market correlation, and less volatility vs market index. Utilizing a dynamic and perpetually improving investment strategy combining increased Portfolio Quality, constant Portfolio analysis, non-stop financial market study, risk and allocation management, along with relentless analysis of performance metrics, mathematics and statistics with the goal of perpetual improvement. Make the Money Make More Money .

### **Q4 Highlights**

Within the 4th Quarter of 2018, the FVAM fund produced a negative return, and was net negative by -1.25%. The fund was down -1.41% in October, positive 0.02% for August and positive 0.14% in December. For the Quarter, the S&P was down just over 14%, while the ACWX (World Index x-USA) was down 12.4%. Although there is no attempt to match the performance or timing of the S&P 500, along with mixed-asset exposure like bonds and credit, currency and/or commodity,


lower risk & volatility, and with equity exposure currently around 90% of the fund, the fund's performance and volatility is analyzed against the index, an all-stock index. The Fund held up very well against the overall markets, US and Globally, which were mostly all down double digits. Another reference point is Warren Buffett's Berkshire Hathaway, BRK/b shares, which was down ~3.75% in the 4th quarter. With the S&P 500 down over 14% in December, the FVAM fund finished the month positive, a small 0.14%, but still positive against a negative and volatile backdrop.

Toward the end of the Year and into early Q1, fund position Celgene caught a buy-out offer from Bristol Myers. This buy-out is still going thru the approval process, but the fund did sell Celgene on this news. Celgene's stock went from a low of \$59/share, up to about \$88 on the offer, and decided to take full advantage of that upside. Not only was Celgene sold, fund took a stake in the acquirer Bristol Myers (BMY) with the stock around \$45/share. The merger between Bristol and Celgene will have to go through months of an approval process and approval is not a given. Shareholders will have a vote, and some big hedge funds with large positions will fight their case for it go thru or not. I am actually for the merger. I like both Bristol and Celgene by themselves, Bristol plus Celgene I believe will become a powerhouse Biotech company. Bristol Myers at the investment price point in the mid 40's should be a great opportunity at a great value. Previous or historical high levels for the stock traded in the mid 70's and I think over the next year or two, it will head back to those levels. Two other investments to highlight in the 4th Quarter were Tesaro (TSRO) and StoneCo (STNE). Tesaro, a cancer-focused drug company, was added to the fund early in the quarter around \$37/share. Within just 3 weeks, Tesaro was sold for close to a double, around \$74/share. Tesaro received a buy-out offer from GlaxoSmithKline for about 4.16 billion, around \$75/share. This gives Glaxo Tesaro's Ovarian Cancer drug Zejula, a new class of drugs known as PARP inhibitors. For now, Glaxo will remain on the fund's watch list, and the fund has a longer term position in Clovis Oncology, which is also in this PARP inhibitor space, and another possible take-out target. Late in the Quarter, the fund started a position in StoneCo, a Brazil-based Financial Tech and payments company, providing cloud-based technology to conduct e-commerce in-store, online and mobile. Company was first noticed when seeing it as a Warren Buffet investment within Berkshire Hathaway, and is also in the fund's focus of Financial Tech ("FinTech") and payments industry. Investment was started just below \$17 share and by mid-March was already trading at over \$40/share. Based on its latest earnings, 4th quarter revenue increased 114% on the year. Can see more about StoneCo here :



<https://finance.yahoo.com/news/stoneco-reports-fourth-quarter-fiscal-200500673.html>

The 4th quarter in the overall markets became very volatile, with the S&P 500 alone down over 14%. One focus of the FVAM fund is to be a non-correlated fund, meaning non-correlated to the overall markets, and creating an independent return. The 4th quarter of 2018 highlighted this focus, especially within the month of December. The S&P 500 in December was down just over 9%, while the FVAM fund finished positive, slightly, but still positive. Some of this had to do with individual stock performance, with one example being Tesaro, which received a buy-out offer with a large premium. Another reason for the outperformance was the fund's small hedge exposure, in this case, small option exposure within Put options on the SPY, an ETF that mirrors the performance of the S&P 500. Put options gain in value if the underlying asset decreases in value. As the SPY was going down, the SPY put options were gaining in value. This helped the fund hold up very well on some of the roughest days of the month.

Below shows reporting created & analyzed within Data Analytics software, Tableau Software, which has data integration into the fund's internal database/spreadsheets. (\*Data as of December 2018)  
High Level allocation heat map and pie chart:




Below shows the further breakdown of only the fund's individual stock exposure. Currently, the heaviest focus of that exposure is allocated towards Technology and Bio-Tech / Pharma investments.




Performance Analysis: Analyzing the breakdown of the Fund's performance, as well as comparisons to other investment vehicles/index, such as the S&P 500, \$BRK-b (Warren Buffett's 'Berkshire


Hathaway'), ACWX which tracks Global Markets minus the US (World x-US), and the Russell 2000 small cap index (\$IWM) FVAM fund, 4th Quarter 2018 , Weekly




FVAM fund, H2 2018 (July - Dec) , Weekly




FVAM fund (green) vs IWM (Russell 2000 Small Cap Index, gray) , Q4 2018, weekly




FVAM fund (green) vs IWM (Russell 2000 Small Cap Index, gray) , Q4 2018, Daily




FVAM fund (green, left) vs BRK/b (blue, right), 2018 Year-to-Date thru early-December, Weekly (\$BRK-B : Berkshire Hathaway B-shares)



FVAM fund (green, left) vs BRK/b (blue, right), Q4 2018, Weekly




FVAM vs BRK/b and relative return (FVAM vs BRK/b), weekly, H2 2018 (Jul-Dec)  
 (excess, positive = outperformance, negative - underperformance)




FVAM (Green) vs S&P500 vs IBB (BioTech Index Fund) vs BRK/b (Berkshire Hathaway) , 4th Quarter - 2018




FVAM vs S&P500 vs BRK/b (Berkshire Hathaway) vs ACWI (World Index) vs IBB (BioTech Index Fund) vs LQD (Bonds) vs EEM (Emerging Markets) , Q4 - 2018




FVAM (top) compared to SPX (S&P 500, bottom), Q4 2018 - Weekly




FVAM vs SPX and relative return (FVAM vs SPX), weekly, H2 2018  
 (\*excess return shows FVAM vs SPX, shows by how much FVAM is outperforming or underperforming the S&P 500)




**FVAM vs IWM (small caps) vs IBB (biotech) vs SPX (S&P 500) vs ACWI (world index) vs ACWX (world x-US) vs LQD (bonds), Weekly, Q4**




**FVAM vs S&P 500 (\$SPX) vs Berkshire Hathaway (\$BRK/b) vs \$ACWX (World Index x-US), weekly, Q4 and Full Year 2018:**




FVAM (green) vs EEM (Emerging Markets) , full-year 2018




FVAM (green) vs LQD (Investment Grade Corporate Bonds), Full-Year 2018




S&P 500 (orange) vs ACWX (World Index minus U.S.), Full-Year 2018, monthly



FVAM vs ACWI (World Index), with Relative Return (excess return), full-year 2018, monthly




FVAM (green) vs ACWX (World Index minus USA, blue) vs S&P 500 (orange) , full-year 2018, monthly returns



Reference 1: FVAM Fund Performance Stats (showing view of December 2018, FVAM vs SPX, Statistics)

The data below, displaying just December 2018 in this example, shows performance statistic data maintained daily, showing the FVAM fund vs the S&P 500, even though FVAM is not trying to match or mimic the actual underlying stocks, within the S&P 500, or match the performance of the index. Data shows performance for FVAM, performance for the S&P 500 (\$SPX), as well as relative performance and mathematical statistics (showing risk & volatility). The chart is displaying daily performance for both FVAM (green) and SPX (blue). Another very important factor for FVAM is to be less volatile than the SPX, which is being analyzed using Statistics, such as Standard Deviation (SDDEV). Excess Return shows relative performance between FVAM and \$SPX (outperformance positive, or underperformance negative). Index C shows plus or minus on a progressive (rolling) basis through the month. The "match (golf)" column also shows that progressive relative performance, but for larger outperformance or underperformance, using a 50bp (+/- 0.5%) differential. For example, if FVAM outperforms the S&P500 by more than 50bps, then FVAM wins that day (the "golf" term is just used to simplify the matchup similar to how match play in golf is scored, did FVAM win the day (or the "hole")).

December 2018



\*SPX (S&P500 index), BRK/B (Berkshire Hathaway) and any other index/fund/investment vehicles' performance using internal data tracking and data from multiple public internet sources, "non-official" data only.

Heat Map for the Dow Jones Industrial Index, showing each stock within the index/sector along with its relative size and weight compared to the overall index (\*as of Feb 2019)



